Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VYFQQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
h1F6-29 MMAE
|
|||||
| Synonyms |
h1F6-29-MMAE
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
B-cell lymphoma [ICD11:2A86]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Vorsetuzumab
|
Antibody Info | ||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
ValOH-Glu-Dpr-MDpr
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 95.28
|
%
|
786-O cells
|
Renal cell carcinoma
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.28% (Day 25) | Positive CD70 expression (CD70+++/++) | ||
| Method Description |
To establish 786-O tumors, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.5 mg/kg single.
|
||||
| In Vivo Model | 786-O CDX model | ||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 31.00 ng/mL | Positive CD70 expression (CD70+++/++) | ||
| Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 33.00 ng/mL | Positive CD70 expression (CD70+++/++) | ||
| Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
| In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.